Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes

被引：0
|
作者：
Herbst, Roy S. [1 ]
Stern, Howard [2 ]
Amler, Lukas [2 ]
Otterson, Gregory [3 ]
Lin, Ming [2 ]
O'Connor, Paula [2 ]
Hainsworth, John [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Ohio State Univ, Columbus, OH 43210 USA
[4] Sarah Cannon Rsrch Inst, Nashville, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).
    Tran, HT
    Zinner, R
    Blumenschein, GR
    Oh, YW
    Papadimitrakopoulou, VA
    Kim, ES
    Lu, C
    Malik, M
    Lum, B
    Herbst, RS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 139S - 139S
  • [42] Two consecutive phase 1-2 studies of cisplatin (P)-based 1st-line chemotherapy (CT) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). The MILES-2P studies.
    Perrone, F.
    Illiano, A.
    Piantedosi, F. V.
    Bearz, A.
    Favaretto, A.
    Lorusso, V.
    Manzione, L.
    Iaffaioli, R. V.
    Valerio, M. R.
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 373S - 373S
  • [43] A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
    Si, Xiaoyan
    Wang, Jinwan
    Cheng, Ying
    Shi, Jianhua
    Cui, Liying
    Zhang, Helong
    Huang, Yunchao
    Liu, Wei
    Chen, Lei
    Zhu, Jiang
    Zhang, Shucai
    Li, Wei
    Sun, Yan
    Wang, Hanping
    Zhang, Xiaotong
    Wang, Mengzhao
    Yang, Lin
    Zhang, Li
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [44] Phase II study of metronomic chemotherapy (MC) with bevacizumab (B) in patients (Pts) with advanced (Adv) nonsquamous non-small cell lung cancer (NS-NSCLC)
    Marquette, Carrie Lee
    Grant, Stefan C.
    DeShazo, Mollie
    Reddy, Vishnu
    Cantor, Alan
    Miley, Debi
    Jerome, Mary
    Robert, Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial
    Rosell, R.
    Gervais, R.
    Vergnenegre, A.
    Massuti, B.
    Felip, E.
    Cardenal, F.
    Garcia Gomez, R.
    Pallares, C.
    Sanchez, J. M.
    Porta, R.
    Cobo, M.
    Di Seri, M.
    Garrido Lopez, P.
    Insa, A.
    De Marinis, F.
    Corre, R.
    Carreras, M.
    Carcereny, E.
    Taron, M.
    Paz-Ares, L. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)
    Kabbinavar, Fairooz
    Fehrenbacher, Louis
    Hainsworth, John
    Kasubhai, Saifuddin
    Kressel, Bruce
    Marsland, Thomas
    Patel, Taral
    Rubin, Mark
    White, Leonard
    Yang, James Chih-Hsin
    Klughammer, Barbara
    Colburn, Dawn
    Miller, Vincent
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : 1411 - 1417
  • [47] A multicenter randomized phase III trial of customized chemotherapy versus standard of care for first-line treatment of elderly patients with advanced non-small cell lung cancer (EPIC)
    Simon, George R.
    Novello, Silvia
    Vavala, Tiziana
    Stinchcombe, Tom
    Gregorc, Vanesa
    Otterson, Gregory Alan
    Gitlitz, Barbara Jennifer
    Langdon, Robert M.
    Bordoni, Rodolfo
    Axelrod, Rita
    Gandara, David R.
    Scagliotti, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Phase I trial of vorinostat in combination with erlotinib for advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations after erlotinib progression (NCT00503971): The TARZO trial
    Reguart, N.
    Isla, D.
    Cardona, A. F.
    Palmero, R.
    Cardenal, F.
    Rolfo, C.
    Montanes, A.
    Queralt, C.
    Carcereny, E.
    Rosell, R.
    EJC SUPPLEMENTS, 2009, 7 (02): : 550 - 550
  • [49] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Tran, Hai T.
    Zinner, Ralph G.
    Blumenschein, George R., Jr.
    Oh, Yun W.
    Papadimitrakopoulou, Vassiliki A.
    Kim, Edward S.
    Lu, Charles
    Malik, Mubashira
    Lum, Bert L.
    Herbst, Roy S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
  • [50] Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
    Kabbinavar, F. F.
    Miller, V. A.
    Johnson, B. E.
    O'Connor, P. G.
    Soh, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345